Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second consensus on medical treatment of metastatic breast cancer.
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H. Beslija S, et al. Among authors: wiltschke c. Ann Oncol. 2007 Feb;18(2):215-25. doi: 10.1093/annonc/mdl155. Epub 2006 Jul 10. Ann Oncol. 2007. PMID: 16831851 Free article. Review.
Third consensus on medical treatment of metastatic breast cancer.
Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; Central European Cooperative Oncology Group (CECOG). Beslija S, et al. Among authors: wiltschke c. Ann Oncol. 2009 Nov;20(11):1771-85. doi: 10.1093/annonc/mdp261. Epub 2009 Jul 16. Ann Oncol. 2009. PMID: 19608616 Free article. Review.
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.
Köstler WJ, Schwab B, Singer CF, Neumann R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C, Zielinski CC. Köstler WJ, et al. Among authors: wiltschke c. Clin Cancer Res. 2004 Mar 1;10(5):1618-24. doi: 10.1158/1078-0432.ccr-0385-3. Clin Cancer Res. 2004. PMID: 15014012
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T. Zielinski C, et al. Among authors: wiltschke c. J Clin Oncol. 2005 Mar 1;23(7):1401-8. doi: 10.1200/JCO.2005.12.106. J Clin Oncol. 2005. PMID: 15735116 Clinical Trial.
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
Köstler WJ, Brodowicz T, Hudelist G, Rudas M, Horvat R, Steger GG, Singer CF, Attems J, Rabitsch W, Fakhrai N, Elandt K, Wiltschke C, Hejna M, Zielinski CC. Köstler WJ, et al. Among authors: wiltschke c. J Cancer Res Clin Oncol. 2005 Jul;131(7):420-8. doi: 10.1007/s00432-005-0670-3. Epub 2005 Apr 29. J Cancer Res Clin Oncol. 2005. PMID: 15864644
69 results